FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134553208> ?p ?o ?g. }

• W3134553208 endingPage "e0247662" @default.
• W3134553208 startingPage "e0247662" @default.
• W3134553208 abstract "Background Diabetes mellitus as a chronic metabolic disease is threatening human health seriously. Although numerous clinical trials have been registered for the treatment of diabetes with stem cells, no articles have been published to summarize the efficacy and safety of mesenchymal stem cells (MSCs) in randomized controlled trials (RCTs). Methods and findings The aim of this study was to systematically review the evidence from RCTs and, where possible, conduct meta-analyses to provide a reliable numerical summary and the most comprehensive assessment of therapeutic efficacy and safety with MSCs in diabetes. PubMed, Web of Science, Ovid, the Cochrane Library and CNKI were searched. The retrieval time was from establishment of these databases to January 4, 2020. Seven RCTs were eligible for analysis, including 413 participants. Meta-analysis results showed that there were no significant differences in the reduction of fasting plasma glucose (FPG) compared to the baseline [mean difference (MD) = -1.05, 95% confidence interval (CI) (-2.26,0.16), P<0.01, I 2 = 94%] and the control group [MD = -0.62, 95%CI (-1.46,0.23), P<0.01, I 2 = 87%]. The MSCs treatment group showed a significant decrease in hemoglobin (Hb) A1c [random-effects, MD = -1.32, 95%CI (-2.06, -0.57), P<0.01, I 2 = 90%] after treatment. Additionally, HbA1c reduced more significantly in MSC treatment group than in control group [random-effects, MD = -0.87, 95%CI (-1.53, -0.22), P<0.01, I 2 = 82%] at the end of follow-up. However, as for fasting C-peptide levels, the estimated pooled MD showed that there was no significant increase [MD = -0.07, 95%CI (-0.30, 0.16), P<0.01, I 2 = 94%] in MSCs treatment group compared with that in control group. Notably, there was no significant difference in the incidence of adverse events between MSCs treatment group and control group [relative risk (RR) = 0.98, 95%CI (0.72, 1.32), P = 0.02, I 2 = 70%]. The most commonly observed adverse reaction in the MSC treatment group was hypoglycemia (29.95%). Conclusions This meta-analysis revealed MSCs therapy may be an effective and safe intervention in subjects with diabetes. However, due to the limited studies, a number of high-quality as well as large-scale RCTs should be performed to confirm these conclusions." @default.
• W3134553208 created "2021-03-15" @default.
• W3134553208 creator A5017794176 @default.
• W3134553208 creator A5021120553 @default.
• W3134553208 creator A5025711732 @default.
• W3134553208 creator A5026132851 @default.
• W3134553208 creator A5041303324 @default.
• W3134553208 creator A5049317806 @default.
• W3134553208 creator A5053533157 @default.
• W3134553208 creator A5054192037 @default.
• W3134553208 creator A5071763816 @default.
• W3134553208 creator A5078591588 @default.
• W3134553208 creator A5080163324 @default.
• W3134553208 creator A5085612104 @default.
• W3134553208 date "2021-03-11" @default.
• W3134553208 modified "2023-10-06" @default.
• W3134553208 title "Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data" @default.
• W3134553208 cites W1774279657 @default.
• W3134553208 cites W1966366851 @default.
• W3134553208 cites W1985674826 @default.
• W3134553208 cites W1988181420 @default.
• W3134553208 cites W1994090721 @default.
• W3134553208 cites W2012304357 @default.
• W3134553208 cites W2025107952 @default.
• W3134553208 cites W2025371271 @default.
• W3134553208 cites W2047786130 @default.
• W3134553208 cites W2073343212 @default.
• W3134553208 cites W2098923148 @default.
• W3134553208 cites W2112270957 @default.
• W3134553208 cites W2126930838 @default.
• W3134553208 cites W2130155157 @default.
• W3134553208 cites W2159911604 @default.
• W3134553208 cites W2170892587 @default.
• W3134553208 cites W2170964813 @default.
• W3134553208 cites W2187102810 @default.
• W3134553208 cites W2334623081 @default.
• W3134553208 cites W2340039039 @default.
• W3134553208 cites W2430871301 @default.
• W3134553208 cites W2483717938 @default.
• W3134553208 cites W2521540515 @default.
• W3134553208 cites W2565447905 @default.
• W3134553208 cites W2731349674 @default.
• W3134553208 cites W2768523617 @default.
• W3134553208 cites W2774743973 @default.
• W3134553208 cites W2805564751 @default.
• W3134553208 cites W2897123771 @default.
• W3134553208 cites W2912751133 @default.
• W3134553208 cites W2923991976 @default.
• W3134553208 cites W2935837182 @default.
• W3134553208 cites W2971195449 @default.
• W3134553208 cites W2999751514 @default.
• W3134553208 cites W4251966062 @default.
• W3134553208 doi "https://doi.org/10.1371/journal.pone.0247662" @default.
• W3134553208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7951834" @default.
• W3134553208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33705413" @default.
• W3134553208 hasPublicationYear "2021" @default.
• W3134553208 type Work @default.
• W3134553208 sameAs 3134553208 @default.
• W3134553208 citedByCount "6" @default.
• W3134553208 countsByYear W31345532082022 @default.
• W3134553208 crossrefType "journal-article" @default.
• W3134553208 hasAuthorship W3134553208A5017794176 @default.
• W3134553208 hasAuthorship W3134553208A5021120553 @default.
• W3134553208 hasAuthorship W3134553208A5025711732 @default.
• W3134553208 hasAuthorship W3134553208A5026132851 @default.
• W3134553208 hasAuthorship W3134553208A5041303324 @default.
• W3134553208 hasAuthorship W3134553208A5049317806 @default.
• W3134553208 hasAuthorship W3134553208A5053533157 @default.
• W3134553208 hasAuthorship W3134553208A5054192037 @default.
• W3134553208 hasAuthorship W3134553208A5071763816 @default.
• W3134553208 hasAuthorship W3134553208A5078591588 @default.
• W3134553208 hasAuthorship W3134553208A5080163324 @default.
• W3134553208 hasAuthorship W3134553208A5085612104 @default.
• W3134553208 hasBestOaLocation W31345532081 @default.
• W3134553208 hasConcept C126322002 @default.
• W3134553208 hasConcept C134018914 @default.
• W3134553208 hasConcept C142724271 @default.
• W3134553208 hasConcept C168563851 @default.
• W3134553208 hasConcept C198826908 @default.
• W3134553208 hasConcept C2776478404 @default.
• W3134553208 hasConcept C2779306644 @default.
• W3134553208 hasConcept C2780473172 @default.
• W3134553208 hasConcept C44249647 @default.
• W3134553208 hasConcept C555293320 @default.
• W3134553208 hasConcept C71924100 @default.
• W3134553208 hasConcept C95190672 @default.
• W3134553208 hasConceptScore W3134553208C126322002 @default.
• W3134553208 hasConceptScore W3134553208C134018914 @default.
• W3134553208 hasConceptScore W3134553208C142724271 @default.
• W3134553208 hasConceptScore W3134553208C168563851 @default.
• W3134553208 hasConceptScore W3134553208C198826908 @default.
• W3134553208 hasConceptScore W3134553208C2776478404 @default.
• W3134553208 hasConceptScore W3134553208C2779306644 @default.
• W3134553208 hasConceptScore W3134553208C2780473172 @default.
• W3134553208 hasConceptScore W3134553208C44249647 @default.
• W3134553208 hasConceptScore W3134553208C555293320 @default.
• W3134553208 hasConceptScore W3134553208C71924100 @default.
• W3134553208 hasConceptScore W3134553208C95190672 @default.

• next